SRI•prnewswire•
Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI)
Summary
LONDON, Dec. 1, 2025 /PRNewswire/ -- Strategic Revenue Insights Inc. - The global landscape of advanced therapeutics is undergoing one of its most transformative phases, led by the rapid rise of next-generation biologics and biosimilars. As healthcare systems confront rising chronic...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 1, 2025 by prnewswire